Table 1.
Demographic characteristics and clinical characteristics of the 12 T1D participants in the phase I clinical study.
| Demographic characteristics | Median (IQR) |
|---|---|
| Age (years) | 40.0 (30.0–49.0) |
| Gender (male/female) | 6/6 (50.0% male) |
| Insulin regimen (CSII/MDI)1 | 6/6 (50.0% CSII) |
| HbA1c (mmol/mol) | 50.4 (41.5–57.5) |
| Glucose data length (hours) | 1113.5 (1059.0–1184.0) |
| Sensor wristband data length (hours) | 832.5 (733.0–953.0) |
| Clinical characteristics | Mean ± SD |
| Time below range (<54 mg/dL) (%) | 0.4 ± 0.3 |
| Time below range (<70 mg/dL) (%) | 2.9 ± 1.9 |
| Time in range ([70, 180] mg/dL) (%) | 63.4 ± 15.8 |
| Time above range (>180 mg/dL) (%) | 33.7 ± 16.9 |
| Low blood glucose index | 0.8 ± 0.5 |
| High blood glucose index | 7.6 ± 4.2 |
| Average daily risk range | 40.4 ± 10.5 |
| Inter-day coefficient of variation (%) | 35.2 ± 4.5 |
| Intra-day coefficient of variation (%) | 30.9 ± 4.8 |
| Mean glucose level (mg/dL) | 161.2 ± 25.9 |
| Median glucose level (mg/dL) | 154.8 ± 26.8 |
1MDI multiple daily injection, CSII continuous subcutaneous insulin infusion.